CooperVision® Expands MiSight® 1 day to Cover Nearly 100%
of Spherical Prescriptions for Children with Myopia
Expanded Range of up to -10.00D Makes Myopia Management
a Possibility for More Children
SOUTHAMPTON, UNITED KINGDOM, 8th JUNE 2021—CooperVision have announced that its MiSight® 1 day contact lenses will be available in higher prescriptions from June 2022. The expanded range—covering -0.25D to -10.00D (0.50D steps after -6.00D)— means that MiSight® 1 day covers 99.97% of prescriptions for Asian children – and 99.97% for Caucasian children – who have myopia and less than 1D of astigmatism. The range extension for this innovative, specially designed lens will allow even more children to benefit from myopia management.
MiSight® 1 day contact lenses are backed by the longest-running soft contact lens study among children. The clinical trial has proven that MiSight® 1 day works for nearly all children with myopia,† cuts the worsening of myopia by half,§ works at any age a child starts treatment (ages 8+),3║ works for as long as the child wears them3║ and that myopia management benefits from MiSight® 1 day are retained after treatment.,¶
With myopia on the rise globally, an increasing number of children may require the higher prescriptions that MiSight® 1 day lenses will offer.
“Every diopter matters, particularly for children whose worsening myopia may have already placed them at a higher risk for conditions such as myopic maculopathy and glaucoma. While early treatment is best, it’s never too late to start,” said Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision, “Even older children starting with MiSight® 1 day have seen the worsening of their myopia cut by half.”║3
As a global leader in myopia control and management for children, CooperVision believes that options must be available for as many children as possible. With MiSight® 1 day’s range extension, eye care professionals in the UK & Ireland and in more than 30 other countries can have even greater impact.
# # #
†90% of myopic eyes respond to MiSight® 1 day treatment; ages 11-15 at start of wear, n=90.
§Using measured and modeled data, pooled across ages (8-17), MiSight® 1 day slowed myopia progression by an average of approximately 50%.
║Children with myopia fit with MiSight® 1 day contact lenses ages 8-15 continued to experience slowed myopia progression as long as they remained in treatment.
¶12 months post-treatment, evidence indicates that no accumulated myopia control benefits were lost following 3 or 6-years of MiSight® 1 day wear (on average, for children aged 8-15 at start of wear). Instead, eye growth reverted to expected, age average myopic progression rates.
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of one day, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.co.uk.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Tom Chapman, Five by Five
023 8082 8525
 CVI Data on file, 2022. SERE coverage of childhood myopia prescriptions with MiSight® 1 day for 104,810 eyes in Asia (China, Korea) and 116,336 eyes in Europe and USA aged 8-18 years.
 Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.
 Arumugam B, Bradley A, Hammond D, Chamberlain P. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2333.
 Chamberlain P, Arumugam B, et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. Optom Vis Sci 2021;98:E-abstract 210049.
 Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130.
 Holden et al, Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-1042.
 Bullimore et al. Myopia Control: Why Each Diopter Matters Optom Vis Sci 2019;96:463–465.